Heidelberg Pharma AG (Seite 516)
eröffnet am 26.10.17 20:25:27 von
neuester Beitrag 11.05.24 00:24:14 von
neuester Beitrag 11.05.24 00:24:14 von
Beiträge: 5.228
ID: 1.265.064
ID: 1.265.064
Aufrufe heute: 32
Gesamt: 589.776
Gesamt: 589.776
Aktive User: 1
ISIN: DE000A11QVV0 · WKN: A11QVV · Symbol: HPHA
3,0000
EUR
+1,01 %
+0,0300 EUR
Letzter Kurs 10.05.24 Tradegate
Neuigkeiten
25.04.24 · EQS Group AG |
05.04.24 · EQS Group AG |
27.03.24 · EQS Group AG |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 17,440 | +44,61 | |
| 1,9750 | +27,42 | |
| 1,8400 | +26,03 | |
| 4,0000 | +25,00 | |
| 0,9052 | +24,10 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2600 | -14,29 | |
| 1,4300 | -14,37 | |
| 5,0639 | -16,13 | |
| 0,5350 | -20,15 | |
| 3,0800 | -23,76 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 57.323.696 von BICYPAPA am 19.03.18 20:42:10Vielen Dank. Die Aussage "Einige noch anhängige Patentfamilien schützen Amanitin-Derivate und chemische
Bausteine, die für die chemische Synthese von ATACs notwendig sind" ist leider sehr allgemein gehalten. Da ich aktuell keine Zeit habe, sämtliche Patente, auch die der anderen Unternehmen, durchzulesen, kann NewKidOnTheBlog die Geschichte vielleicht etwas verkürzen. Andernfalls müßte man mal bei HDP nachfragen ... oder in den sauren Apfel beißen und doch noch alle Patentschriften selber durchlesen, wenn wieder mehr Zeit ist.
Bausteine, die für die chemische Synthese von ATACs notwendig sind" ist leider sehr allgemein gehalten. Da ich aktuell keine Zeit habe, sämtliche Patente, auch die der anderen Unternehmen, durchzulesen, kann NewKidOnTheBlog die Geschichte vielleicht etwas verkürzen. Andernfalls müßte man mal bei HDP nachfragen ... oder in den sauren Apfel beißen und doch noch alle Patentschriften selber durchlesen, wenn wieder mehr Zeit ist.
Antwort auf Beitrag Nr.: 57.323.363 von Joschka Schröder am 19.03.18 20:10:48
http://heidelberg-pharma.com/wp-content/uploads/2011/02/2017…
Zur Patentsituation
Zur Patensituation habe ich auf der Heidelberg Pharma Webseite folgenden link gefunden. Vielleicht hilft das schon ein wenig weiter.http://heidelberg-pharma.com/wp-content/uploads/2011/02/2017…
Antwort auf Beitrag Nr.: 57.276.559 von NewKidOnTheBlog am 14.03.18 15:18:53Vielen Dank für die Links. Einige Arbeiten sind mir bereits bekannt, die restliche Literatur werde ich gelegentlich durchlesen. Hinsichtlich der Patentsituation, mit der ich mich noch nicht näher beschäftigt habe, fällt auf, dass zahlreiche Unternehmen Amatoxin-ADC´s zum Patent angemeldet haben (u.a. Novartis, Sorrento Therapeutics und Agensys). Da Du offensichtlich aus dem HDP-Umfeld stammst, könntest Du dazu evt. etwas Erhellendes schreiben. Wilex/HDP ist bekanntlich schon deutlich länger als ein Jahrzehnt mit Amatoxin-Themen befaßt ist, so dass vorstellbar ist, dass keine Schutzrechte mehr für Amatoxin als therapeutisches Toxin existieren.
Antwort auf Beitrag Nr.: 57.314.975 von BICYPAPA am 19.03.18 06:18:08
19 March, 2018
Data from non-clinical studies indicated that WX-UK1, the active metabolite of RHB-107 (formerly MESUPRON), is a potent and specific inhibitor of five human serine proteases, suggesting new potential therapeutic applications in oncology and inflammatory digestive diseases
TEL-AVIV, Israel / RALEIGH, NC, March 19, 2018 RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, today announced the presentation of a poster at the American Association for Cancer Research (AACR) 2018 Annual Meeting. The abstract (number 4200) will be presented by Mark L. Levitt, MD, Ph.D., Medical Director, Oncology at RedHill, on Tuesday, April 17, 2018 from 1:00 PM to 5:00 PM CDT, at McCormick Place, Chicago, IL.
The abstract1 presentation, entitled ‘New potential therapeutic applications of WX-UK1, as a specific and potent inhibitor of human trypsin-like proteases’, describes data from non-clinical studies concluding that WX-UK1, the active metabolite of RHB-107 (formerly MESUPRON) (INN: upamostat), is a potent and specific inhibitor of five human serine proteases (trypsin-3, trypsin-2, trypsin-1, matriptase-1 and trypsin-6). Several of these serine proteases are associated with cancer progression and metastasis. The non-clinical studies suggest new potential therapeutic applications of WX-UK1 in oncology and inflammatory gastrointestinal diseases. The abstract was authored by scientists from the Department of Molecular Biology and Genetics of Aarhus University in collaboration with RedHill2.
RHB-107 is a proprietary, first-in-class, orally-administered potent serine protease inhibitor, presenting a new non-cytotoxic approach to cancer therapy, as well as other indications of high unmet need, such as inflammatory digestive diseases and inflammatory lung diseases. RHB-107 has undergone several Phase I studies and two Phase II proof-of-concept studies in cancer patients.
With the recent identification of several serine proteases as high-affinity molecular targets, RedHill is evaluating utilization of RHB-107 in both cancer and inflammatory digestive diseases.
About RHB-107 (upamostat):
RHB-107 (formerly MESUPRON) (INN: upamostat) is a proprietary, first-in-class, orally-administered potent inhibitor of several serine proteases targeting cancer and inflammatory gastrointestinal diseases. Protease inhibitors have been shown to play key roles in tumor invasion and the metastasis process. High levels of certain proteases are associated with poor prognosis in various solid tumor cancers, such as pancreatic, gastric, breast and prostate cancers. RHB-107 was previously granted FDA Orphan Drug designation for the treatment of pancreatic cancer. RHB-107 presents a new non-cytotoxic approach to cancer therapy with several potential mechanisms of action to inhibit tumor invasion and metastasis. RHB-107 has undergone several Phase I studies and two Phase II proof-of-concept studies. The first Phase II study was in locally-advanced, non-metastatic pancreatic cancer and the second study in metastatic breast cancer in combination with first-line chemotherapeutic agents. RedHill was granted a new patent from the United States Patent and Trademark Office (USPTO) directed to a combination of RHB-107, YELIVA®, RedHill’s two Phase II-stage investigational compounds, and a known antibiotic. RedHill acquired the exclusive worldwide rights to RHB-107, excluding China, Hong Kong, Taiwan and Macao, from Germany’s Heidelberg Pharmaceuticals (formerly WILEX AG) for all indications.
Redhill Mesupron
RedHill Announces Poster Presentation on New Potential Therapeutic Applications of RHB-107 at the AACR 2018 Annual Meeting19 March, 2018
Data from non-clinical studies indicated that WX-UK1, the active metabolite of RHB-107 (formerly MESUPRON), is a potent and specific inhibitor of five human serine proteases, suggesting new potential therapeutic applications in oncology and inflammatory digestive diseases
TEL-AVIV, Israel / RALEIGH, NC, March 19, 2018 RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, today announced the presentation of a poster at the American Association for Cancer Research (AACR) 2018 Annual Meeting. The abstract (number 4200) will be presented by Mark L. Levitt, MD, Ph.D., Medical Director, Oncology at RedHill, on Tuesday, April 17, 2018 from 1:00 PM to 5:00 PM CDT, at McCormick Place, Chicago, IL.
The abstract1 presentation, entitled ‘New potential therapeutic applications of WX-UK1, as a specific and potent inhibitor of human trypsin-like proteases’, describes data from non-clinical studies concluding that WX-UK1, the active metabolite of RHB-107 (formerly MESUPRON) (INN: upamostat), is a potent and specific inhibitor of five human serine proteases (trypsin-3, trypsin-2, trypsin-1, matriptase-1 and trypsin-6). Several of these serine proteases are associated with cancer progression and metastasis. The non-clinical studies suggest new potential therapeutic applications of WX-UK1 in oncology and inflammatory gastrointestinal diseases. The abstract was authored by scientists from the Department of Molecular Biology and Genetics of Aarhus University in collaboration with RedHill2.
RHB-107 is a proprietary, first-in-class, orally-administered potent serine protease inhibitor, presenting a new non-cytotoxic approach to cancer therapy, as well as other indications of high unmet need, such as inflammatory digestive diseases and inflammatory lung diseases. RHB-107 has undergone several Phase I studies and two Phase II proof-of-concept studies in cancer patients.
With the recent identification of several serine proteases as high-affinity molecular targets, RedHill is evaluating utilization of RHB-107 in both cancer and inflammatory digestive diseases.
About RHB-107 (upamostat):
RHB-107 (formerly MESUPRON) (INN: upamostat) is a proprietary, first-in-class, orally-administered potent inhibitor of several serine proteases targeting cancer and inflammatory gastrointestinal diseases. Protease inhibitors have been shown to play key roles in tumor invasion and the metastasis process. High levels of certain proteases are associated with poor prognosis in various solid tumor cancers, such as pancreatic, gastric, breast and prostate cancers. RHB-107 was previously granted FDA Orphan Drug designation for the treatment of pancreatic cancer. RHB-107 presents a new non-cytotoxic approach to cancer therapy with several potential mechanisms of action to inhibit tumor invasion and metastasis. RHB-107 has undergone several Phase I studies and two Phase II proof-of-concept studies. The first Phase II study was in locally-advanced, non-metastatic pancreatic cancer and the second study in metastatic breast cancer in combination with first-line chemotherapeutic agents. RedHill was granted a new patent from the United States Patent and Trademark Office (USPTO) directed to a combination of RHB-107, YELIVA®, RedHill’s two Phase II-stage investigational compounds, and a known antibiotic. RedHill acquired the exclusive worldwide rights to RHB-107, excluding China, Hong Kong, Taiwan and Macao, from Germany’s Heidelberg Pharmaceuticals (formerly WILEX AG) for all indications.
Antwort auf Beitrag Nr.: 57.314.966 von BICYPAPA am 19.03.18 06:12:56
Globally, the radiopharmaceutical medicine market is expected to reach USD 13.8 billion by 2024, according to a new report by Grand View Research. The market is driven by increasing number of cancer cases and rising awareness about nuclear medicine. Radiopharmaceuticals are pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis and therapeutics. They contain a radioactive substance that is used in the treatment of cancer and cardiac and neurological disorders. The conventional chemotherapy methods are being replaced by more convenient therapeutic radiopharmaceuticals for oncology and cancer treatment, which opens up new avenues in the radiopharmaceuticals market. The convenience of the treatment with minimally invasive techniques attracts more patients towards radiopharmaceuticals mode of treatment as compared to chemotherapy.
Nuclear medicine also helps detect the presence of disease in its earliest stages and is one of the most favorable drivers of the market, as public awareness about chronic diseases is increasing. Increasing diagnostic nuclear medicine procedures is supporting the growth of the market and experts indicate that use of radiopharmaceuticals in diagnosis is growing at over 10% per year throughout the world.
The past decade has seen a mammoth rise in cancer cases and other lifestyle disorders in APAC and thus, this regions is expected to register fastest growth in nuclear medicine space in comparison to other global countries. Research reports elaborate that nuclear medicine practice in Japan is in high demand with a significant increase in cancer cases in recent years. Furthermore, China and India are boosting the growth of the Asia Pacific nuclear medicine market with increasing demand for treatment and diagnosis of Alzheimer’s and Parkinson’s disease.
With many unique advantages, radiopharmaceuticals offer clear potential for players in emerging Asian countries as there is a need to broaden healthcare coverage and address unmet medical needs. Realizing the market potential, recently several Asian companies have been increasing their focus on radiopharmaceuticals.
Entering the Japanese market, Telix Pharmaceuticals , an Australian biopharmaceutical company focused on the development of radio pharmaceutical diagnostic and therapeutic interventions recently announced the establishment Telix Pharmaceuticals (Japan) (“Telix Japan”) and the appointment of the first two members of the Japanese leadership team.
Telix Japan is wholly-owned operating subsidiary of Telix Pharmaceuticals Limited. The purpose of the subsidiary is to support the Company’s Japanese clinical and radiopharmaceutical manufacturing activities and to establish a commercial footprint in the Japan, an important market for Telix’s products. Telix is developing an advanced portfolio of oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer.
Recently Telix Pharmaceuticals also inked a manufacturing deal with JFE Engineering Corporation in order to develop and make Telix’s products available to Japanese cancer patients.
To lead the Telix Japan activities, Dr. Shintaro Nishimura and Dr. Takeshi Oka have been appointed as President and Chief Operating Officer, and Chief Medical Officer (Japan), respectively.
Speaking to BioSpectrum Asia Magazine, Dr Shintaro Nishimura, President and Chief Operating Officer of Telix Japan, elaborated on APAC’s oncology market as well as opportunities and challenges in the Japanese market for radiopharmaceutical products.
Why was Japan chosen as a destination for expansion?
Telix chose Japan as a destination for expansion because it is potentially a significant market for Telix’s products.
Historically, Japan has been slow to adopt advanced nuclear medicine due to restrictions on importing nuclear material, however, recent healthcare policy developments in the country has recognized the cost-effectiveness of molecularly-targeted radiation (MTR) technology. As such, there is significant momentum to develop domestic capacity to address the oncology needs of Japan’s rapidly ageing patient population.
In light of these macro factors, there is significant commercial opportunity for Telix in Japan, and considerable interest in our oncology pipeline from leading nuclear medicine clinics. As such, the company established a Japanese subsidiary in January 2018, and we hope to use this high level of clinical engagement to obtain the additional data required to support product approval in Japan in the future.
What according to you are the major opportunities and challenges for Telix products in the Japanese market?
Japan is the prospectively the second largest market for Telix’s products after the United States due to its growing cancer patient population. However, one obstacle faced by radiopharmaceutical companies is the difficulty of importing radioactive isotopes into the country. As such, there is significant clinical interest in the prospect of domestic production of new medical isotopes and, consequently, novel imaging and therapeutic radiopharmaceutical products, especially in oncology.
To address this issue, we were pleased to announce that Telix signed a manufacturing partnership with JFE Engineering Corporation (JFE), an engineering and manufacturing company with extensive expertise in radiopharmaceutical manufacturing, in December 2017. This partnership will see the production of 89Zr (Zirconium) in mid-2018 - the first commercial production of this isotope in Japan. The Zirconium isotope is critical to Telix’s diagnostic imaging portfolio - particularly for TLX-250, our lead program for imaging for renal cancer.
Please throw some light on Telix's further expansion plans
The company’s growth strategy involves commercial collaboration and partnering with leading radiation oncology and pharmaceutical companies that have an active interest in Telix and the radiation oncology space generally. Clinical and academic collaborations are also important; hence our recent announcement with Memorial Sloan Kettering Cancer Centre, one of the world’s leading cancer hospitals. We are also selectively expanding our portfolio through selective acquisitions or additional partnerships, while also investigating indication expansion opportunities for assets within our existing portfolio.
Please give us an overview of Telix's product pipeline
Telix is an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR). The Company is developing an advanced portfolio of oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. The company is listed on the Australian Securities Exchange as “TLX”.
The company’s portfolio of clinical programs include:
TLX-250: for the diagnosis and treatment of renal (kidney) cancer, which is the Company’s lead program and currently in Phase III and Phase II
TLX-591: for the treatment of prostate cancer, currently in Phase II
TLX-101: for the treatment of brain (glioblastoma) cancer, currently in Phase I
How is the APAC market for oncology products?
Cancer is an increasingly important health issue in the APAC region given the ageing population and changes to lifestyles associated with growing economic development and epidemiologic transition, and this is especially the case in Japan. Japan needs cost-effective therapeutic tools and radiopharmaceuticals have a very favorable cost-benefit equation. Generally speaking the global pharmaceutical industry has recognized the growth opportunity for both diagnostic and therapeutic medicine in Asia’s healthcare market. Asia remains price-sensitive but the market is also under-served. In particular, for Telix’s lead program TLX-250, the region is estimated to have the fastest growth rate for the kidney cancer drugs market – over 6% - due to the increasing patient base and growing disease awareness. Prostate cancer is also on the rise and part of our clinical activities in Japan is better understanding the differences in prostate cancer biology between “western” and Japanese men.
In general, Asian countries have lower rates of kidney cancer compared to North American and European countries, but Japan shows higher incidences of the disease – and most other cancers – than other Asian countries.
Artikel Redectane
Dr Shintaro Nishimura, President and Chief Operating Officer of Telix JapanGlobally, the radiopharmaceutical medicine market is expected to reach USD 13.8 billion by 2024, according to a new report by Grand View Research. The market is driven by increasing number of cancer cases and rising awareness about nuclear medicine. Radiopharmaceuticals are pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis and therapeutics. They contain a radioactive substance that is used in the treatment of cancer and cardiac and neurological disorders. The conventional chemotherapy methods are being replaced by more convenient therapeutic radiopharmaceuticals for oncology and cancer treatment, which opens up new avenues in the radiopharmaceuticals market. The convenience of the treatment with minimally invasive techniques attracts more patients towards radiopharmaceuticals mode of treatment as compared to chemotherapy.
Nuclear medicine also helps detect the presence of disease in its earliest stages and is one of the most favorable drivers of the market, as public awareness about chronic diseases is increasing. Increasing diagnostic nuclear medicine procedures is supporting the growth of the market and experts indicate that use of radiopharmaceuticals in diagnosis is growing at over 10% per year throughout the world.
The past decade has seen a mammoth rise in cancer cases and other lifestyle disorders in APAC and thus, this regions is expected to register fastest growth in nuclear medicine space in comparison to other global countries. Research reports elaborate that nuclear medicine practice in Japan is in high demand with a significant increase in cancer cases in recent years. Furthermore, China and India are boosting the growth of the Asia Pacific nuclear medicine market with increasing demand for treatment and diagnosis of Alzheimer’s and Parkinson’s disease.
With many unique advantages, radiopharmaceuticals offer clear potential for players in emerging Asian countries as there is a need to broaden healthcare coverage and address unmet medical needs. Realizing the market potential, recently several Asian companies have been increasing their focus on radiopharmaceuticals.
Entering the Japanese market, Telix Pharmaceuticals , an Australian biopharmaceutical company focused on the development of radio pharmaceutical diagnostic and therapeutic interventions recently announced the establishment Telix Pharmaceuticals (Japan) (“Telix Japan”) and the appointment of the first two members of the Japanese leadership team.
Telix Japan is wholly-owned operating subsidiary of Telix Pharmaceuticals Limited. The purpose of the subsidiary is to support the Company’s Japanese clinical and radiopharmaceutical manufacturing activities and to establish a commercial footprint in the Japan, an important market for Telix’s products. Telix is developing an advanced portfolio of oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer.
Recently Telix Pharmaceuticals also inked a manufacturing deal with JFE Engineering Corporation in order to develop and make Telix’s products available to Japanese cancer patients.
To lead the Telix Japan activities, Dr. Shintaro Nishimura and Dr. Takeshi Oka have been appointed as President and Chief Operating Officer, and Chief Medical Officer (Japan), respectively.
Speaking to BioSpectrum Asia Magazine, Dr Shintaro Nishimura, President and Chief Operating Officer of Telix Japan, elaborated on APAC’s oncology market as well as opportunities and challenges in the Japanese market for radiopharmaceutical products.
Why was Japan chosen as a destination for expansion?
Telix chose Japan as a destination for expansion because it is potentially a significant market for Telix’s products.
Historically, Japan has been slow to adopt advanced nuclear medicine due to restrictions on importing nuclear material, however, recent healthcare policy developments in the country has recognized the cost-effectiveness of molecularly-targeted radiation (MTR) technology. As such, there is significant momentum to develop domestic capacity to address the oncology needs of Japan’s rapidly ageing patient population.
In light of these macro factors, there is significant commercial opportunity for Telix in Japan, and considerable interest in our oncology pipeline from leading nuclear medicine clinics. As such, the company established a Japanese subsidiary in January 2018, and we hope to use this high level of clinical engagement to obtain the additional data required to support product approval in Japan in the future.
What according to you are the major opportunities and challenges for Telix products in the Japanese market?
Japan is the prospectively the second largest market for Telix’s products after the United States due to its growing cancer patient population. However, one obstacle faced by radiopharmaceutical companies is the difficulty of importing radioactive isotopes into the country. As such, there is significant clinical interest in the prospect of domestic production of new medical isotopes and, consequently, novel imaging and therapeutic radiopharmaceutical products, especially in oncology.
To address this issue, we were pleased to announce that Telix signed a manufacturing partnership with JFE Engineering Corporation (JFE), an engineering and manufacturing company with extensive expertise in radiopharmaceutical manufacturing, in December 2017. This partnership will see the production of 89Zr (Zirconium) in mid-2018 - the first commercial production of this isotope in Japan. The Zirconium isotope is critical to Telix’s diagnostic imaging portfolio - particularly for TLX-250, our lead program for imaging for renal cancer.
Please throw some light on Telix's further expansion plans
The company’s growth strategy involves commercial collaboration and partnering with leading radiation oncology and pharmaceutical companies that have an active interest in Telix and the radiation oncology space generally. Clinical and academic collaborations are also important; hence our recent announcement with Memorial Sloan Kettering Cancer Centre, one of the world’s leading cancer hospitals. We are also selectively expanding our portfolio through selective acquisitions or additional partnerships, while also investigating indication expansion opportunities for assets within our existing portfolio.
Please give us an overview of Telix's product pipeline
Telix is an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR). The Company is developing an advanced portfolio of oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. The company is listed on the Australian Securities Exchange as “TLX”.
The company’s portfolio of clinical programs include:
TLX-250: for the diagnosis and treatment of renal (kidney) cancer, which is the Company’s lead program and currently in Phase III and Phase II
TLX-591: for the treatment of prostate cancer, currently in Phase II
TLX-101: for the treatment of brain (glioblastoma) cancer, currently in Phase I
How is the APAC market for oncology products?
Cancer is an increasingly important health issue in the APAC region given the ageing population and changes to lifestyles associated with growing economic development and epidemiologic transition, and this is especially the case in Japan. Japan needs cost-effective therapeutic tools and radiopharmaceuticals have a very favorable cost-benefit equation. Generally speaking the global pharmaceutical industry has recognized the growth opportunity for both diagnostic and therapeutic medicine in Asia’s healthcare market. Asia remains price-sensitive but the market is also under-served. In particular, for Telix’s lead program TLX-250, the region is estimated to have the fastest growth rate for the kidney cancer drugs market – over 6% - due to the increasing patient base and growing disease awareness. Prostate cancer is also on the rise and part of our clinical activities in Japan is better understanding the differences in prostate cancer biology between “western” and Japanese men.
In general, Asian countries have lower rates of kidney cancer compared to North American and European countries, but Japan shows higher incidences of the disease – and most other cancers – than other Asian countries.
Trading Spotlight
Antwort auf Beitrag Nr.: 57.283.276 von BICYPAPA am 15.03.18 06:16:16
Gesamter Artikel:
https://www.biospectrumasia.com/influencers/34/10466/cancer-…
Australia’s Telix Pharmaceuticals is developing an advanced portfolio of radiopharmaceuticals products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Recently Telix announced the establishment its Japanese subsidiary and the appointment of the first two members of the Japanese leadership team. Speaking to BioSpectrum Asia Magazine, Dr Shintaro Nishimura, President and Chief Operating Officer of Telix Japan, elaborated on APAC’s oncology market as well as opportunities and challenges in the Japanese market for radiopharmaceutical products.
Redectane TLX-250 in Japan
'Cancer is an increasingly important health issue in the APAC region’Gesamter Artikel:
https://www.biospectrumasia.com/influencers/34/10466/cancer-…
Australia’s Telix Pharmaceuticals is developing an advanced portfolio of radiopharmaceuticals products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Recently Telix announced the establishment its Japanese subsidiary and the appointment of the first two members of the Japanese leadership team. Speaking to BioSpectrum Asia Magazine, Dr Shintaro Nishimura, President and Chief Operating Officer of Telix Japan, elaborated on APAC’s oncology market as well as opportunities and challenges in the Japanese market for radiopharmaceutical products.
Antwort auf Beitrag Nr.: 57.282.883 von BICYPAPA am 14.03.18 23:59:42
http://www.telixpharma.com/investors/asx-announcements/
Telix Brief zur Jahreshaptversammlung
Hier der link zur Telix Jahreshauptversammlung. Ich bitte euch weitere Einzelheiten zu Redectane (TLX-250) dem link zu entnehmen.http://www.telixpharma.com/investors/asx-announcements/
Antwort auf Beitrag Nr.: 57.189.595 von BICYPAPA am 05.03.18 15:20:03
[Melbourne (Australia) and Nijmegen (Netherlands) – 15 February 2018. Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has today announced a clinical collaboration with Radboud University Medical Center (“Radboudumc”).
Telix is developing 89Zr-girentuximab (TLX-250) for the purpose of imaging clear cell renal cell cancer (ccRCC) with Positron Emission Tomography (PET). Radboudumc and Telix will collaborate on several clinical projects in relation to TLX-250, including leading the pre-Phase III bridging/dosimetry study for TLX-250, participating as a key adviser for the Phase III study, as well as the IMPACT-RCC study (NCT02228954) to better understand how molecular imaging can be used to measure therapeutic treatment response in metastatic kidney cancer.
Telix Co-Founder and CMO Dr. Andreas Kluge stated, “Radboudumc has been a clinical leader in the use of 89Zr-Girentuximab (TLX-250) in the clinic and their patient experience underpins much of the confidence we have in the imaging agent, particularly the change in isotope to a radiometal for superior image quality, sensitivity and patient convenience. We have worked closely with Radboudumc as part of activating our clinical activity for TLX-250 in Europe.”
Professor Peter Mulders, Chairman of the Department of Urology at Radboudumc noted, “We are pleased to be working with Telix to progress this very important technology from a clinical perspective. This international collaboration lays the foundation for the completion of product development of 89Zr-Girentuximab and we are delighted to be part of bringing this technology to renal cancer patients in the Netherlands and beyond.”
As part of the collaboration, Telix will fund a clinical fellowship position at the Department of Radiology and Nuclear Medicine of the Radboudumc to oversee the various activities around the collaboration. The Radboudumc Technology Center imaging facility will also be a key partner, with its cutting-edge technology and expertise for pre-clinical and clinical imaging.
Telix Redectane Cooperation
Telix Pharmaceuticals and Radboud University Medical Centre Conclude Clinical Collaboration Agreement [Melbourne (Australia) and Nijmegen (Netherlands) – 15 February 2018. Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has today announced a clinical collaboration with Radboud University Medical Center (“Radboudumc”).
Telix is developing 89Zr-girentuximab (TLX-250) for the purpose of imaging clear cell renal cell cancer (ccRCC) with Positron Emission Tomography (PET). Radboudumc and Telix will collaborate on several clinical projects in relation to TLX-250, including leading the pre-Phase III bridging/dosimetry study for TLX-250, participating as a key adviser for the Phase III study, as well as the IMPACT-RCC study (NCT02228954) to better understand how molecular imaging can be used to measure therapeutic treatment response in metastatic kidney cancer.
Telix Co-Founder and CMO Dr. Andreas Kluge stated, “Radboudumc has been a clinical leader in the use of 89Zr-Girentuximab (TLX-250) in the clinic and their patient experience underpins much of the confidence we have in the imaging agent, particularly the change in isotope to a radiometal for superior image quality, sensitivity and patient convenience. We have worked closely with Radboudumc as part of activating our clinical activity for TLX-250 in Europe.”
Professor Peter Mulders, Chairman of the Department of Urology at Radboudumc noted, “We are pleased to be working with Telix to progress this very important technology from a clinical perspective. This international collaboration lays the foundation for the completion of product development of 89Zr-Girentuximab and we are delighted to be part of bringing this technology to renal cancer patients in the Netherlands and beyond.”
As part of the collaboration, Telix will fund a clinical fellowship position at the Department of Radiology and Nuclear Medicine of the Radboudumc to oversee the various activities around the collaboration. The Radboudumc Technology Center imaging facility will also be a key partner, with its cutting-edge technology and expertise for pre-clinical and clinical imaging.
Antwort auf Beitrag Nr.: 57.114.342 von Joschka Schröder am 25.02.18 15:59:02BCMA ist ein super target und ADC ist caeteris paribus besser als CAR-T
voellig inverstanden
zu deinen weiteren Fragen:
Top slides zum Thema Linker/site specific conjugation
http://worldadc-usa.com/wp-content/uploads/sites/99/2016/10/…
http://worldadc-usa.com/wp-content/uploads/sites/99/2016/10/…
HP Patent
WO 2012/119787 A1
weiter zu dem Thema, gute reviews (open source)
https://www.ncbi.nlm.nih.gov/pubmed/24423619
Site-specific antibody drug conjugates for cancer therapy, Panowski 2014
und
www.mdpi.com/2227-9059/5/4/64/pdf
Site-Specific Antibody Conjugation for ADC and Beyond, Zhou 2017
und schliesslich die Genentech Publikation zu THIOMAB in Nature 2008
voellig inverstanden
zu deinen weiteren Fragen:
Top slides zum Thema Linker/site specific conjugation
http://worldadc-usa.com/wp-content/uploads/sites/99/2016/10/…
http://worldadc-usa.com/wp-content/uploads/sites/99/2016/10/…
HP Patent
WO 2012/119787 A1
weiter zu dem Thema, gute reviews (open source)
https://www.ncbi.nlm.nih.gov/pubmed/24423619
Site-specific antibody drug conjugates for cancer therapy, Panowski 2014
und
www.mdpi.com/2227-9059/5/4/64/pdf
Site-Specific Antibody Conjugation for ADC and Beyond, Zhou 2017
und schliesslich die Genentech Publikation zu THIOMAB in Nature 2008
Antwort auf Beitrag Nr.: 57.255.511 von watchingtheflood am 12.03.18 18:40:50Allgemein gesagt kommt nur jeder 10. Produktekandidat im. Biotechbereich am Schluss auf den Markt, die anderen 9 Kandidaten muss man auf Null abschreiben. Das weiß auch Hopp und sollte jeder wissen der in Biotech investiert. Bis zum Markteinztitt kostet Biotech nur Geld. Bei den beiden Lizenzvereinbarungen von HDP liegt das Risiko bei den Lizenznehmern, der Gewinn bei HDP liegt zwischen derzeit praktisch Null und dem angegebenen Wert also jeweils ca 300 Mio.
Zu Hopp. Der Artikel blendet leider einiges aus. Die Beteiligung Cosmo ist zur Zeit ca 110 Mio wert, ca 8 mal höher als Hopp bezahlt hat. Bei Wilex sind nach wie vor 2 Kandidaten auslizensiert. Viele Kandidaten von Hopp sind erst am Anfang oder in der Mitte angelangt, ein Produktezyklus dauert in der Regel 10-15 Jahre bis zum Markt. Per heute kann man über die Investments von Hopp noch kein Urteil fällen. Halte den Artikel MM für tendenziös.
Zu Hopp. Der Artikel blendet leider einiges aus. Die Beteiligung Cosmo ist zur Zeit ca 110 Mio wert, ca 8 mal höher als Hopp bezahlt hat. Bei Wilex sind nach wie vor 2 Kandidaten auslizensiert. Viele Kandidaten von Hopp sind erst am Anfang oder in der Mitte angelangt, ein Produktezyklus dauert in der Regel 10-15 Jahre bis zum Markt. Per heute kann man über die Investments von Hopp noch kein Urteil fällen. Halte den Artikel MM für tendenziös.
Durchsuchen
25.04.24 · EQS Group AG · Heidelberg Pharma |
17.04.24 · EQS Group AG · Heidelberg Pharma |
05.04.24 · EQS Group AG · Heidelberg Pharma |
27.03.24 · EQS Group AG · Heidelberg Pharma |
27.03.24 · wO Chartvergleich · Super Micro Computer |
